tetano
Editor, Senior Moderator
J Med Virol
. 2024 Sep;96(9):e29926.
doi: 10.1002/jmv.29926. Harnessing PROTACs to combat H5N1 influenza: A new frontier in viral destruction
Nobendu Mukerjee[SUP] 1 [/SUP], Swastika Maitra[SUP] 2 [/SUP], Dattatreya Mukherjee[SUP] 3 [/SUP], Arabinda Ghosh[SUP] 4 [/SUP], Athanasios T Alexiou[SUP] 5 [/SUP], Nanasheb D Thorat[SUP] 6 [/SUP]
Affiliations
H5N1, a highly pathogenic avian influenza virus, poses an ongoing and significant threat to global public health, primarily due to its potential to cause severe respiratory illness and high mortality rates in humans. Despite extensive efforts in vaccination and antiviral therapy, H5N1 continues to exhibit high mutation rates, resulting in recurrent outbreaks and the emergence of drug-resistant strains. Traditional antiviral therapies, such as neuraminidase inhibitors and M2 ion channel blockers, have demonstrated limited efficacy, necessitating the exploration of innovative therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) emerge as a novel and promising approach, leveraging the ubiquitin-proteasome system to selectively degrade pathogenic proteins. Unlike conventional inhibitors that only block protein function, PROTACs eliminate the target protein, providing a sustained therapeutic effect and potentially reducing the development of resistance. This paper offers a comprehensive examination of the current landscape of H5N1 infections, detailing the pathogenesis and challenges associated with existing treatments. It further explores the mechanism of action, design, and therapeutic potential of PROTACs in inhibiting H5N1. By targeting essential viral proteins, such as hemagglutinin and the RNA-dependent RNA polymerase complex, PROTACs hold the potential to revolutionize the treatment of H5N1 infections, offering a new frontier in antiviral therapy.
Keywords: H5N1 influenza; PROTACs; antiviral therapy; protein degradation; viral pathogenesis.
. 2024 Sep;96(9):e29926.
doi: 10.1002/jmv.29926. Harnessing PROTACs to combat H5N1 influenza: A new frontier in viral destruction
Nobendu Mukerjee[SUP] 1 [/SUP], Swastika Maitra[SUP] 2 [/SUP], Dattatreya Mukherjee[SUP] 3 [/SUP], Arabinda Ghosh[SUP] 4 [/SUP], Athanasios T Alexiou[SUP] 5 [/SUP], Nanasheb D Thorat[SUP] 6 [/SUP]
Affiliations
- PMID: 39295251
- DOI: 10.1002/jmv.29926
H5N1, a highly pathogenic avian influenza virus, poses an ongoing and significant threat to global public health, primarily due to its potential to cause severe respiratory illness and high mortality rates in humans. Despite extensive efforts in vaccination and antiviral therapy, H5N1 continues to exhibit high mutation rates, resulting in recurrent outbreaks and the emergence of drug-resistant strains. Traditional antiviral therapies, such as neuraminidase inhibitors and M2 ion channel blockers, have demonstrated limited efficacy, necessitating the exploration of innovative therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) emerge as a novel and promising approach, leveraging the ubiquitin-proteasome system to selectively degrade pathogenic proteins. Unlike conventional inhibitors that only block protein function, PROTACs eliminate the target protein, providing a sustained therapeutic effect and potentially reducing the development of resistance. This paper offers a comprehensive examination of the current landscape of H5N1 infections, detailing the pathogenesis and challenges associated with existing treatments. It further explores the mechanism of action, design, and therapeutic potential of PROTACs in inhibiting H5N1. By targeting essential viral proteins, such as hemagglutinin and the RNA-dependent RNA polymerase complex, PROTACs hold the potential to revolutionize the treatment of H5N1 infections, offering a new frontier in antiviral therapy.
Keywords: H5N1 influenza; PROTACs; antiviral therapy; protein degradation; viral pathogenesis.